entertainment -WSS

entertainment

author：hotspot 2025-10-01 14:37:56 - browse：14625

Moderna's mResvia vaccine — The FDA has approved Moderna’s RSV vaccine for older adults. Moderna

The Food and Drug Administration on Friday approved Moderna’s vaccine to protect older adults against respiratory syncytial virus, or RSV, making this the company’s second licensed product.

The Moderna RSV vaccine, which will be marketed under the name mResvia, was approved for adults 60 and older. It is made using the same messenger RNA platform as Moderna’s other licensed product, its Covid-19 vaccine Spikevax.

“The FDA approval of our second product, mResvia, builds on the strength and versatility of our mRNA platform,” Moderna CEO Stéphane Bancel said in a statement.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Virginia high school admissions case could be legal follow

WSS

How to save PrEP access — and even expand it

For longer

UnitedHealth argues against case alleging wrongful AI care denials

United colonoscopy coverage change 'may cost lives,' doctors say

Listen: More tumult at BIO & coercive care for sickle cell patients

What does generative AI mean for health care? We asked experts

entertainment

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Apple is now the first public company to be valued at $3 trillion

Medicare details structure of new drug price negotiation program

Peter Hotez and the public health issue of online harassment

H5N1 virus can be tracked in retail milk, scientists say

Sports medicine is finally prioritizing gender equality

H5N1 bird flu outbreak: Second human case reported, in Michigan

BioMarin wins approval for gene therapy to treat hemophilia A

23andMe had bad news about my health. I wish a person had delivered it

New air purifier tech could be key to improving indoor air quality

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

Wikipedia

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Questions and answers about ramping up H5N1 bird flu vaccine

ASCO eve: Let’s set the table for this year's meeting

Walensky prepares to leave CDC — and Congress — behind

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

Readout Newsletter: H5N1 bird flu vaccine, Cytokinetics, Gilead

entertainment

hotspot

focus

focus